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Background: XB130 is a newly discovered adaptor protein for intracellular signal transduction; it is involved in gene
regulation, cell proliferation, cell survival, cell migration, and tumorigenesis. However, its expression and role in
pancreatic ductal adenocarcinoma (PDAC) have not been investigated. The present study was designed to clarify
the prognostic significance of XB130 expression in PDAC.
Methods: A total of 76 consecutive patients with surgically resected PDAC were retrospectively reviewed. XB130
expression was detected by immunohistochemical analysis on the paraffin-embedded tumour sections. Correlation
between the expression of XB130 and clinicopathological parameters was analyzed.
Results: XB130 expression was significantly upregulated in PDAC(56.5%, 43/76) compared to normal pancreas
(0%, 0/15; P < 0.05). Increased XB130 expression was correlated with lymph node metastasis (P = 0.017), distant
metastasis (P = 0.0024), high tumour-node-metastasis (TNM) stage (P =0.001), and high tumour grade (P = 0.013).
The survival of 43 patients with high XB130 expression was significantly worse than that of the 33 patients with low
XB130 expression (P = 0.001). Univariate analysis showed that high XB130 expression (P = 0.0045), tumour size
(P = 0.024), distant metastasis (P = 0.003), TNM stage (P = 0.002) and lymphatic metastasis (P = 0.016) were independent
prognostic factors of postoperative survival. Multivariate analysis using the Cox proportional hazards model showed
that high XB130 expression and distant metastasis (P = 0.0239) were significant independent risk factors.
Conclusions: XB130 was overexpressed in the PDAC. XB130 is a promising pathological marker for the prediction of
outcome in patients with PDAC.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the
most devastating human malignancies. Surgical resection
remains the only potentially curative therapeutic option.
At the time of initial diagnosis, only a minority of pa-
tients with PDAC are at a disease stage that can still po-
tentially be cured by resection [1]. Even if a potentially
curative resection can be performed, the 5-year overall
survival is low at 10 to 25% [1-3]. Because of the lack
of methods for the early diagnosis and limited know-
ledge on the biological features of PDAC, the majority of* Correspondence: Zhangjianli6551@126.com
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unless otherwise stated.patients are not diagnosed properly until the advanced
stage [4]. Prognostic factors for PDAC have been well
studied, and include gender, age, size and location of the
tumour, stage, lymph node metastasis, tumour grade, and
serum carbohydrate antigen 19-9 level [1,2,5,6]. However,
none of these established clinical markers have correlated
with outcome and therapeutic response in patients with
PDAC [7].
XB130 is a newly discovered adaptor protein for intra-
cellular signal transduction; it is involved in gene regula-
tion, cell proliferation, cell survival, cell migration, and
tumorigenesis [8]. XB130 is strongly expressed in the
spleen and thyroid of humans, while it shows weak ex-
pression in the kidney, brain, lung, and pancreas [9].
XB130 has been detected in follicular and papillaryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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human oesophageal squamous cell carcinoma [11], hepa-
tocellular carcinoma [12] as well as in gastric cancer [13].
In gastric cancer, reduced XB130 protein expression is a
prognostic biomarker for shorter survival and a higher re-
currence rate in patients with gastric cancer, as well as for
the response to chemotherapy [13]. In oesophageal squa-
mous cell carcinoma (ESCC), the expression of XB130 in
ESCC cells may affect cell cycle progression and impact
prognosis of patients with ESCC [11].
This study examines the expression of XB130 in 76 re-
sected PDAC patients by immunohistochemistry and in-




We analysed 76 consecutive patients with PDAC who
underwent surgical resection in the Department of Ge-
neral Surgery at the affiliated hospital of Qingdao Uni-
versity between March 2003 and February 2009. Patients
were excluded from the study if they had a previous his-
tory of another malignancy, or had received chemother-
apy or radiotherapy before surgical resection, or had
undergone palliative resection. Surgical procedures were
as follows: 43 patients were treated by conventional pan-
creatoduodenectomy, 18 were treated by pylorus pre-
serving pancreatoduodenectomy, 8 were treated by distal
pancreatectomy, and 4 were treated by total pancrea-
tectomy. The age of the patients ranged from 23 to 72
years, and the median age was 64 years. All surgical spe-
cimens were reviewed and classified according to the
World Health Organization classification by an experi-
enced pathologist who was unaware of clinical or imaging
findings. Pathological tumour-node-metastasis (TNM)
stages were established using the International System for
Staging Pancreatic ductal adenocarcinoma adopted by the
American Joint Committee on Cancer and the Union
Internationale Centre le Cancer [13]. Of the total patients,
12, 39, 19 and 6 had stage I, II, III and IV tumours, re-
spectively. Postoperative adjuvant chemotherapy with
gemcitabine, 5-fluorouracil(5-Fu) and oral administration
of tegafur (a fluorouracil derivative drug) were adminis-
tered to 21, 10 and 1 patients, respectively. The day of
surgery was considered the starting day for measuring
postoperative survival.
A control group consisted of seven patients with be-
nign pancreatic lesions (one patient with intraductal
papillary-mucinous adenoma, two patients with solid-
pseudopapillary tumour, one patient with lymphoplasma-
cytic sclerosing pancreatitis, one patient with chronic
sclerosing pancreatitis, one patient with inflammatory
pseudotumour and one patient with pancreatic endo-
crine cell tumour), five cases of pancreatic lesions fromtraumatic injury of the pancreas and an organ donor pro-
gram from three previously healthy individuals (two fe-
male, one male; median age of 31 years, with a range of 18
to 56 years) when there was no suitable recipient. The
study protocol was approved by the institution of the affil-
iated hospital of Qingdao University.
Immunohistochemistry
Rabbit anti-XB130 Ab (1:100; (Abnova, Shanghai, China)
was used as primary antibody. Immunohistochemical stai-
ning was performed with an immunoperoxidase method
using the ABC complex as the manufacturer’s recom-
mended protocol. Briefly, each section was dewaxed with
xylene. Endogenous peroxidase was blocked by incubating
the sections in 0.3% hydrogen peroxidase in absolute
methanol at room temperature for 30 minutes. After hy-
dration in decreasing concentrations of ethanol in water,
the sections were washed in 0.01 M PBS, pH 7.4. Antigen
retrieval was achieved by waterbath pretreatment at 80°C
for 20 minutes in 0.01 M citrate buffer (pH 6.0). The sec-
tions were washed twice with PBS and 2% horse or goat
serum in PBS was applied for 30 minutes at room tem-
perature to prevent non-specific staining. The sections
were then incubated with dilutions of the anti-XB130 in
PBS with 1% bovine serum albumin for 16 hours at 4°C.
The sections were washed three times with PBS, incu-
bated with the biotinylated secondary antibodies, and then
washed three times with PBS. All sections then received
ABC complex for 30 minutes. After washing with PBS
three times, the sections were finally reacted with diami-
nobenzidine substrate for 10 minutes for visualisation,
rinsed with tap water, counterstained with haematoxylin,
and mounted. Reaction products were not present when
non-immune serum or PBS was used instead of the pri-
mary antibodies.
Immunohistochemistry results were evaluated by scan-
ning each slide under low power magnification (×10)
to identify regions containing positive immunoreactiv-
ity. Immunostaining was further evaluated at high po-
wer magnification (×200). The percentages of positively
stained cells ≤25% were considered to be low expression,
and >25% were considered to be high expression. XB130
immunostaining was evaluated independently by two indi-
viduals blinded to the clinical parameters.
Statistical analysis
The results are presented as mean ± SD. Statistical ana-
lysis was performed using the Student’s t test, the chi2
test, and the Mann-Whitney U test where appropriate.
Univariate and multivariate survival analyses were per-
formed using the Cox proportional hazards regression
model. Furthermore, backward stepwise multivariate ana-
lysis was used to find independent prognostic factors. A
value of P < 0.05 was considered significant. Statistical
Table 1 Relation between XB130 expression and
clinicopathologic variables in pancreatic cancer patients
XB130 expression
Variables Number High (n) Low (n) P value
Gender ns
Male 48 31 17
Female 28 12 16
Age (years) ns
<60 45 29 16
≥60 31 14 17
TNM stage 0.001
I 12 3 9
II 39 18 21
III 19 16 3
IV 6 6 0
Tumour size ns
≤2 cm 50 32 18
>2 cm 26 11 15
T classification 0.013
T1/T2 15 4 11
T3/T4 61 39 22
N classification 0.017
N0 25 8 17
N1 51 35 16
Histologic differentiation ns
Well (G1) 30 18 12
Moderate (G2) 28 15 13
Poor (G3) 18 10 8
Distant metastasis 0.0024
M0 60 29 31
M1 16 14 2
Lymphatic invasion ns
Yes 14 8 6
No 59 35 24
Vascular invasion ns
Yes 18 10 8
No 58 33 25
Perineural invasion ns
Yes 8 3 5
No 68 40 28
Chemotherapy ns
No 32 20 12
Yes 44 23 21
ns, Not significant; TNM, tumour-node-metastasis.
Zhang et al. World Journal of Surgical Oncology 2014, 12:49 Page 3 of 5
http://www.wjso.com/content/12/1/49analysis of the data was performed using SPSS software
version 10.0 (SPSS Inc., Chicago, IL, USA).
Results
Immunohistochemical analysis
The immunohistochemical analysis of XB130 was per-
formed on the 76 primary lesions with PDAC and seven
resected lesions with benign pancreatic diseases, five
cases of pancreatic lesions from traumatic injury of the
pancreas and an organ donor program from three previ-
ously healthy individuals. XB130 immunostaining was
detected in carcinoma cells in the tumour tissues. It was
localised predominantly on the cytoplasm. In the 76 pa-
tients with PDAC, high XB130 expression was recog-
nized in 56.5% (43/76) of cases, which was significantly
high than the XB130 expression in the normal pancreas
(0%, 0/15) (P < 0.05).
Prognostic value of XB130 expression and
clinicopathologic variables
We investigated the relationship between XB130 protein
expression and various clinicopathological features in
PDAC (Table 1). No correlation could be observed be-
tween tumor XB130 expression and age, gender, tumour
size, histologic differentiation, lymphatic invasion, vascular
invasion, perineural invasion and chemotherapy status. In
contrast, increased XB130 expression was correlated with
lymph node metastasis (P = 0.017), distant metastasis (P =
0.0024), high TNM stage (P = 0.001), and high tumour
grade (P = 0.013).
The survival curves of the patients, grouped according
to the level of XB130 staining in their tumours, are shown
in Figure 1. The high XB130 expression group had aFigure 1 Overall survival of 76 pancreatic ductal adenocarcinoma
patients in relation to XB130 protein expression. Kaplan-Meier
survival curves for patients who had undergone surgical resection of
pancreatic ductal adenocarcinoma, stratified according to the level of
expression of XB30 in their tumours. Patients with low tumor XB130
protein expression had a significantly better prognosis than patients
with high tumour XB130 protein expression (log-rank test, P = 0.001).
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pression group (log-rank test, P = 0.001).
Univariate analysis showed that high XB130 expression
(P = 0.0045), tumour size (P = 0.024), distant metastasis
(P = 0.003), TNM stage (P = 0.002) and lymphatic metas-
tasis (P = 0.016) were independent prognostic factors of
postoperative survival. Multivariate analysis using the Cox
proportional hazards model showed that high XB130 ex-
pression (P = 0.0043) and distant metastasis (P = 0.0239)
were significant independent risk factors (Table 2).
Discussion and conclusions
To establish proper therapeutic modalities for PDAC, an
accurate assessment of the factors affecting tumouTNM
staging system, which is defined by tumour size, tumour
progression, lymph node involvement, and distant me-
tastasis [14] is useful for PDAC classification, the out-
come is poor for patients even in the low-stage (I and II)
groups [15]. Therefore, the prognostic use of severalTable 2 Prognostic factors in Cox’s proportional hazards mod
Univariate
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HR, hazard ratio; TNM, tumour-node-metastasis.molecular markers for PDAC classification have been in-
vestigated [16], although none proved useful for predict-
ing patient prognosis [7,17]. We undertook the present
study to determine whether XB130 expression is the a
valid biological indicator of the aggressiveness of PDAC.
Recent studies have shown that high XB130 expression
is significantly associated with cell proliferation, angioge-
nesis and poor outcome in patients with various human
neoplasms [8,10-13]. However, little is known regarding
the clinical significance of XB130 expression in human
cancer, such as PDAC. In the present study, XB130 was
highly expressed in PDAC cells compared with normal
pancreatic cells, and the high expression of XB130 pro-
tein within PDAC cells closely correlated with high TNM
stage, distant metastasis, high T and N classification and
dismal postoperative survival. These results suggest that
over-expression of XB130 might enhance cell motility and
invasiveness. It is also clearly demonstrated that the ex-
pression of XB130 was a significant independent factor forel
Multivariate
P HR 95% CI P
0.438
0.572
0.002 1.84 1.546-2.874 0.056
0.024 1.632 1.145-2.247 0.134
0.386
0.016 1.357 0.964-2.832 0.106





0.0045 2.375 1.263-3.874 0.0043
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cally resected PDAC.
A previous review has summarised the immunohis-
tochemical biomarkers with prognostic significance in
patients with PDAC and concluded that none of the mo-
lecular markers can be recommended for routine clinical
use [18]. Therefore, whether the presence of these mo-
lecular markers has any prognostic implications remains
unclear. The results of our study identified the XB130 as
an independent prognostic factor for predicting poor
outcome. Although a recent retrospective study has de-
monstrated that patients with adjuvant therapy have more
adverse prognostic factors than those without adjuvant
therapy [19], XB130 was associated with prognostic sig-
nificance regardless of adjuvant therapy.
In conclusion, high expression of XB130 (measured by
immunohistochemical staining) can serve as an independ-
ent prognostic marker to predict poor outcome after sur-
gical resection and may be an important clinical marker of
therapy for PDAC. Inhibition of XB130 function may ar-
rest tumour growth, and XB130 represents an attractive
target for adjuvant therapy in the future.
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